It could be a very tough year for pharmaceutical firms, which face a slew of patent expiries and...
It could be a very tough year for pharmaceutical firms, which face a slew of patent expiries and new costs from healthcare reforms. Market research firm CreditSights pegs Bristol-Myers (BMY) and Eli Lilly (LLY) as likely to be next year's hardest-hit pharmas, while Abbott (ABT) and J&J (JNJ) will remain relatively sheltered.
From other sites
Video at CNBC.com (Aug 21, 2015)
at CNBC.com (Jun 1, 2015)
Video at CNBC.com (May 26, 2015)
Video at CNBC.com (Mar 5, 2015)
Video at CNBC.com (Mar 4, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs